Follistatin 344, also known as FST-344 or simply Follistatin, is a glycoprotein originally identified in follicular fluid. It is encoded by the FST gene and is characterized by its ability to bind and neutralize members of the TGF-beta superfamily, particularly activins. Follistatin is synthesized in various tissues, including the liver and muscle, and is involved in numerous physiological processes. Researchers have primarily focused on its role in muscle growth and development, as well as its potential therapeutic applications in muscle-wasting conditions. Studies have shown that Follistatin 344 can promote muscle hypertrophy and improve muscle strength, making it a compound of interest in the field of muscle biology. Additionally, it has been investigated for its effects on the insulin-like growth factor (IGF) axis, which plays a crucial role in growth and metabolism. The mechanism of action of Follistatin 344 involves the inhibition of activins and myostatin, both of which are negative regulators of muscle growth. By binding to these proteins, Follistatin prevents them from interacting with their receptors, thereby promoting muscle cell proliferation and differentiation. This action is mediated through pathways that include the SMAD signaling cascade. Pharmacokinetic data on Follistatin 344 is limited, but researchers have noted that its stability and bioavailability can vary depending on the route of administration. The compound is generally considered to have a short half-life, necessitating frequent administration for sustained effects. Current research on Follistatin 344 is focused on its potential therapeutic applications, particularly in the treatment of muscle-wasting diseases such as muscular dystrophy. However, it is not yet approved for clinical use, and its regulatory status varies by region. Ongoing studies aim to better understand its safety profile and long-term effects.